Bruce A. Cohen
Vorstandsvorsitzender bei Statim Pharmaceuticals, Inc.
Profil
Bruce A.
Cohen was the founder and had founded VitaPath Genetics, Inc. in 2009, where he held the title of President & Chief Executive Officer.
He is currently the Chief Executive Officer at Statim Pharmaceuticals, Inc. since 2018, a Director at Iconic Therapeutics, Inc., and an Independent Director at Cerca Insights Sdn.
Bhd.
since 2012.
Mr. Cohen has held former positions as President & Chief Executive Officer at Cellerant Therapeutics, Inc., Acacia Biosciences, Inc., and Bionano Genomics, Inc. He was also the Chief Executive Officer at PrIME Biologics Pte Ltd.
from 2017 to 2019, Chief Executive Officer at Baysient LLC, Chairman & Treasurer at Viropro, Inc. from 2014 to 2018, Chairman at Xagenic, Inc. from 2012 to 2013, and Director at Chrono Therapeutics, Inc. He served as a Director at Rapid Micro Biosystems, Inc. from 2018 to 2021.
Additionally, he held positions at Baxter International, Inc. as a Planning Analyst, SEQUUS Pharmaceuticals, Inc. as Vice President-Business Unit Management, Genesoft Pharmaceuticals, Inc. as Chief Financial Officer, and Vitel International Holding Co., Inc. as President & Chief Operating Officer.
Mr. Cohen's education includes a graduate degree from Tufts University in 1980, an undergraduate degree from Tufts University in 1975, and an MBA from Harvard Business School in 1982.
Aktive Positionen von Bruce A. Cohen
Unternehmen | Position | Beginn |
---|---|---|
Cerca Insights Sdn. Bhd.
Cerca Insights Sdn. Bhd. Miscellaneous Commercial ServicesCommercial Services Cerca Insights Sdn. Bhd. provides behavioral pharmacology paradigms to research institutes. It services include phenotyping new rodent models, sar support, identifying and optimising leads, behavioural assay development, PK screens and PD analysis, early safety assessment, ageing studies and chronic dosing. The company was founded by Anil K. Ratty in 2008 and is headquartered in Bayan Lepas, Malaysia. | Direktor/Vorstandsmitglied | 29.03.2010 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | Direktor/Vorstandsmitglied | - |
Statim Pharmaceuticals, Inc. | Vorstandsvorsitzender | 01.11.2018 |
Ehemalige bekannte Positionen von Bruce A. Cohen
Unternehmen | Position | Ende |
---|---|---|
RAPID MICRO BIOSYSTEMS, INC. | Direktor/Vorstandsmitglied | 01.01.2021 |
PrIME Biologics Pte Ltd.
PrIME Biologics Pte Ltd. BiotechnologyHealth Technology PrIME Biologics Pte Ltd. develops disposable therapeutic plasma manufacturing process. Its process doubles product yields while increasing product safety and removing viruses, bacteria, endotoxins, and prions. The firm’s process reduces the time it takes to produce multiple plasma products from days to hours. The company is headquartered in Singapore. | Vorstandsvorsitzender | 01.03.2019 |
Baysient LLC
Baysient LLC Packaged SoftwareTechnology Services Baysient LLC is a private company that creates cloud-based software to facilitate individualized dosing of anti-inflammatory mabs to improve outcomes in patients. The company is based in Fort Myers, FL. The software uses Bayesian models, routine lab results, and demographics to individualize dosing to a specified target trough-level output to a PK dashboard. Steven A. Molnar has been the CEO of the company since 2019. | Vorstandsvorsitzender | 01.01.2019 |
VIROPRO INC. | Vorsitzender | 01.07.2018 |
Chrono Therapeutics, Inc.
Chrono Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Chrono Therapeutics, Inc. produces transdermal drug products. It is a pharmaceutical company with a vision of transforming disease and addiction management to become the market leader in programmable passive transdermal drug delivery that offers real-time behavioral support. The company was founded by Guy DiPierro in 2004 and is headquartered in Hayward, CA. | Direktor/Vorstandsmitglied | - |
Ausbildung von Bruce A. Cohen
Tufts University | Graduate Degree |
Harvard Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
BAXTER INTERNATIONAL INC. | Health Technology |
VIROPRO INC. | Health Technology |
RAPID MICRO BIOSYSTEMS, INC. | Producer Manufacturing |
BIONANO GENOMICS, INC. | Health Technology |
Private Unternehmen | 13 |
---|---|
SEQUUS Pharmaceuticals, Inc.
SEQUUS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million. | Health Technology |
Genesoft Pharmaceuticals, Inc. | Commercial Services |
Cellerant Therapeutics, Inc.
Cellerant Therapeutics, Inc. Medical SpecialtiesHealth Technology Cellerant Therapeutics, Inc. develops stem cell-based cellular and antibody therapeutics for blood disorders and cancer. The firm focuses on curative therapies for seriously ill patients and is developing a cell-based medicine as a treatment for chemotherapy and radiation-induced neutropenia as well as for Acute Radiation Syndrome. The company was founded by Irving L. Weissman in 2003 and is headquartered in San Carlos, CA. | Health Technology |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Chrono Therapeutics, Inc.
Chrono Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Chrono Therapeutics, Inc. produces transdermal drug products. It is a pharmaceutical company with a vision of transforming disease and addiction management to become the market leader in programmable passive transdermal drug delivery that offers real-time behavioral support. The company was founded by Guy DiPierro in 2004 and is headquartered in Hayward, CA. | Commercial Services |
Acacia Biosciences, Inc.
Acacia Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Acacia Biosciences, Inc. provided drug discovery technology. The company was headquartered in Richmond, CA. | Commercial Services |
Vitel International Holding Co., Inc. | Communications |
VitaPath Genetics, Inc.
VitaPath Genetics, Inc. Medical/Nursing ServicesHealth Services VitaPath Genetics is developing a family of DNA tests to help individuals reduce the risk of serious and life-threatening disease. The company's first product is a genetic test to identify risk factors that are associated with a common birth defect called Spina Bifida and which can be safely corrected with low-risk vitamin supplementation under the care of a physician. At VitaPath, it mission is to focus only on genetic mutations that are shown to be biologically functional and that can be remediated with minimal risk. In doing so, it can improve the quality of life for customers and reduce the overall cost of healthcare. | Health Services |
Cerca Insights Sdn. Bhd.
Cerca Insights Sdn. Bhd. Miscellaneous Commercial ServicesCommercial Services Cerca Insights Sdn. Bhd. provides behavioral pharmacology paradigms to research institutes. It services include phenotyping new rodent models, sar support, identifying and optimising leads, behavioural assay development, PK screens and PD analysis, early safety assessment, ageing studies and chronic dosing. The company was founded by Anil K. Ratty in 2008 and is headquartered in Bayan Lepas, Malaysia. | Commercial Services |
PrIME Biologics Pte Ltd.
PrIME Biologics Pte Ltd. BiotechnologyHealth Technology PrIME Biologics Pte Ltd. develops disposable therapeutic plasma manufacturing process. Its process doubles product yields while increasing product safety and removing viruses, bacteria, endotoxins, and prions. The firm’s process reduces the time it takes to produce multiple plasma products from days to hours. The company is headquartered in Singapore. | Health Technology |
Xagenic, Inc.
Xagenic, Inc. Medical SpecialtiesHealth Technology Xagenic, Inc. develops the first lab-free molecular diagnostic platform. Its automated diagnostic platform will enable widespread decentralized testing to be performed outside of clinical laboratories. The firm's amplified redox assay detection technology utilizes electrochemical detection methods and does not rely on optical detection components or enzymatic amplification; crude samples can be analyzed with minimal sample processing. The company was founded by Shana O. Kelley and Edward Hartley Sargent in 2010 and is headquartered in Toronto, Canada. | Health Technology |
Baysient LLC
Baysient LLC Packaged SoftwareTechnology Services Baysient LLC is a private company that creates cloud-based software to facilitate individualized dosing of anti-inflammatory mabs to improve outcomes in patients. The company is based in Fort Myers, FL. The software uses Bayesian models, routine lab results, and demographics to individualize dosing to a specified target trough-level output to a PK dashboard. Steven A. Molnar has been the CEO of the company since 2019. | Technology Services |
Statim Pharmaceuticals, Inc. |